Tyra Biosciences, Inc. TYRA Other Development Programs — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tyra Biosciences, Inc.'s other development programs — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tyra Biosciences, Inc.'s other development programs — research and development expense?
- Tyra Biosciences, Inc. (TYRA) reported other development programs — research and development expense of $849K in Q1 2026.
- How has Tyra Biosciences, Inc.'s other development programs — research and development expense changed year-over-year?
- Tyra Biosciences, Inc.'s other development programs — research and development expense increased by 65.2% year-over-year, from $514K to $849K.
- What is the long-term trend for Tyra Biosciences, Inc.'s other development programs — research and development expense?
- Over 2 years (2023 to 2025), Tyra Biosciences, Inc.'s other development programs — research and development expense has grown at a 3.5% compound annual growth rate (CAGR), from $2.45M to $2.62M.
- What does other development programs — research and development expense mean?
- This metric represents the aggregate costs incurred for research and development activities specifically allocated to the company's secondary or exploratory drug development programs outside of its primary lead candidates. It captures the financial resources dedicated to advancing early-stage pipeline assets, including personnel costs, laboratory supplies, and clinical trial expenses associated with these specific projects. Monitoring this expenditure provides insight into the company's investment strategy for diversifying its therapeutic portfolio and its commitment to long-term innovation beyond its flagship programs.